Through clinical subgroup analyses, SLC7A11 could distinguish survival differences of patients in all age groups, clinical stages I–IV, grades 3–4, T1–4, N0, and M0 stages (Figure 3F–N), which indicated that SLC7A11 had good applicability in RCC prognostic analysis. The gene discussed is SLC7A11; the disease is renal cell carcinoma.